SEO for Weight Loss & Semaglutide Clinics.
Semaglutide changed weight-loss medicine overnight, and then changed again in 2024 when the FDA declared the shortage resolved. Every weight-loss clinic we talk to is trying to figure out what they can still advertise, what keywords still work, and how to compete with the telehealth brands piling into the category. We built a post-2024 SEO playbook around exactly those questions.
$5,000/mo retainer floor · Calendly-first booking · Founder reviews every inquiry personally.
Monthly patient searches — weight loss category
~29,100
anchored by "weight loss clinic near me" (27,100/mo), plus semaglutide clinic, ozempic clinic, and GLP-1 provider variants
Marketing-intent searches — weight-loss agency
~420/mo
clinic owners actively searching for weight-loss-specific marketing help. Rising since mid-2024 as the category regulatory picture shifts.
Avg CPC — "weight loss clinic near me"
$9.38
Google Ads policy restricts weight-loss advertising, which means paid is capped and organic + Map Pack are where the real volume goes
Every clinic is pitching semaglutide. The winners stopped pitching and started ranking.
Between 2022 and 2024, semaglutide turned weight-loss medicine into the fastest-growing cash-pay category in healthcare. Telehealth brands launched by the dozen. Med spas added GLP-1 injections to their menus. Compounded semaglutide created a supply chain that briefly made the drug available to almost every licensed prescriber. The result was a search landscape flooded with content — most of it thin, claim-heavy, and written before anyone read the FTC or FDA guidance.
Then 2024 happened. The FDA declared the semaglutide shortage resolved, tightening the rules under which compounded semaglutide could be prescribed. Eli Lilly and Novo Nordisk sued compounding pharmacies. State boards issued enforcement updates. Meta and Google both updated their weight-loss-ad policies. Clinics that had built their SEO and ad strategy on aggressive semaglutide claims lost visibility — some of it through algorithm moves, some of it through policy-driven de-ranking, some of it through explicit takedown notices. The landscape shifted mid-year.
The clinics that have held (or grown) their organic visibility through that shift did three things. First, they moved off pure drug-name targeting ("ozempic weight loss," "semaglutide near me") toward outcome and program targeting ("medical weight loss [city]," "GLP-1 medical weight management"). Second, they rewrote claim language to match the current FTC Section 5 and FDA substantiation rules. Third, they invested in local Map Pack and reviews because paid channels (Google Ads especially) are structurally constrained for weight-loss advertising. Our practice runs all three.
Post-2024 weight-loss SEO — built for the current regulatory picture.
The weight-loss SEO playbook we run now is not the 2022 playbook. Too much changed. Every part of the program below accounts for the current FDA, FTC, and platform-policy posture — and for the fact that Google Ads is partially closed to this category, which shifts the weight toward organic and Map Pack.
GBP — Weight Loss Service + Medical Clinic stack
Primary: Weight Loss Service, secondaries: Medical Clinic, Hormone Therapy Clinic (where applicable), Wellness Center. Service-menu field structured around medical weight loss, GLP-1 programs, and any surgical-referral pathway you offer. Posts weekly — provider-authored content on protocol, lab work cadence, and the "what to expect" journey.
Program-first content (not drug-first content)
We build your site around your medical weight-loss PROGRAM — the intake, labs, monitoring, coaching — not around a specific drug. Drug-name content (Wegovy, Ozempic, Mounjaro, Zepbound, compounded semaglutide) sits as supporting pages under the program hub. This structure holds up through policy changes and ranks more durably than drug-only pages.
Compliant claim language across the site
Every page gets an FTC Section 5 audit before it ships. Claims like "lose 20 lbs in 2 months," "guaranteed weight loss," "replaces diet and exercise" are flagged and rewritten. Results language is substantiated or removed. The net effect: content that can't trigger a warning letter while still reading as clinically confident.
Transparent pricing (the big conversion lever)
"Semaglutide cost," "weight loss clinic cost," "how much is Wegovy without insurance" — these are enormous-volume queries that most clinics avoid. A transparent pricing page (program pricing, per-month ranges, what's included) ranks for those queries, pre-qualifies patients, and reduces no-shows. In this category the no-show rate matters — a lot of semaglutide seekers shop multiple clinics simultaneously.
Outcome-review library with explicit disclaimers
Patient outcome testimonials are powerful and regulatorily dangerous in this category. We build a review-collection and display workflow with FTC-compliant disclaimers, representative-results language, and no cherry-picked outlier stories. The resulting library actually holds up in a compliance audit AND converts prospects at a better rate than disclaimer-less raw reviews.
Positioning against national telehealth brands
Every local weight-loss clinic is now competing with Hims, Noom, Ro, Sequence, Found, Form Health, and more. The SEO play: comparison content, transparent local advantages (same-provider continuity, in-person labs, prescription backup when one GLP-1 is out of stock), and Map Pack dominance that telehealth brands can't touch. We build all of it.
Four 2025–26 realities that generalist healthcare-marketing agencies haven't caught up to.
Most healthcare marketing agencies we talk to are still running the 2022 weight-loss playbook. They haven't updated their content templates since the FDA shortage-resolution decision. They haven't adjusted to Meta and Google's revised weight-loss ad policies. They're still recommending aggressive drug-name SEO strategies that are now structurally deranking.
The four items below are specific to the current (mid-2026) regulatory and competitive picture. If your agency isn't raising these unprompted, they're running a stale playbook on your clinic.
The compounded semaglutide content decision
Whether your clinic can or should prescribe compounded semaglutide in 2026 is a clinical and legal question we don't answer — but if you do prescribe it, the marketing content needs specific positioning. Compounded cannot be marketed as equivalent to Wegovy / Ozempic; it needs distinct language. We build the content inside those constraints so your program isn't exposed even if the landscape tightens further.
Google Ads policy is structurally restrictive for weight loss
Google's Healthcare and Medicines policy restricts a lot of weight-loss advertising (specific drug names, results-based copy, aggressive lead-gen flows). Meta is more permissive. The implication: your paid-channel mix tilts toward Meta + SEO for weight-loss clinics, which increases the ROI of organic more than in any other vertical we work with.
Semaglutide shortage status changes your keyword target
When the drug is in shortage, "compounded semaglutide near me" is the high-volume query. When it's not, patients search "weight loss clinic," "medical weight loss," and specific branded names ("Wegovy provider near me"). We track the FDA status and adjust the target set — most agencies don't.
Multi-drug programming is now the durable positioning
Clinics that position as "semaglutide clinics" are tied to one drug's availability and policy posture. Clinics that position as "medical weight loss" with semaglutide, tirzepatide (Mounjaro/Zepbound), phentermine, and behavior programs in the mix are durable across shortage cycles and policy shifts. We recommend and build the broader positioning.
Audit → claim cleanup → program-first content → local dominance.
The sequence for a weight-loss account leads with compliance cleanup, because most sites we take over have claim-language exposure that's blocking rankings and creating regulatory risk simultaneously. Fix that first, then the rest of the program compounds.
- Step 01
Discovery + current-site claim audit
30-minute discovery call plus a focused audit of every claim on the site — weight-loss outcomes, drug-name usage, before/after language, result-timeline claims. Output: a flagged list of changes with FTC/FDA context and a risk level per claim.
- Step 02
Claim cleanup + rewrite sprint
2–3 weeks of tight rewrites. Every flagged claim gets rewritten to what's substantiable or removed. Result testimonials get disclaimers and representative-results language. Drug-specific pages get equivalence-language cleanup. This alone improves rankings on most accounts because Google's quality raters downrank the aggressive language.
- Step 03
Program-first content architecture
Hub page: your medical weight-loss program. Spoke pages: semaglutide / GLP-1 protocols, tirzepatide / Mounjaro / Zepbound, phentermine programs, behavior / coaching / nutrition. City pages for each market. 10–14 pages typically ship in the first 75 days.
- Step 04
Pricing transparency + insurance-question handling
Dedicated pricing page covering program costs, per-month ranges, what's included. Parallel page answering the insurance question (most weight-loss programs are cash-pay; being clear about it reduces no-shows and pre-qualifies patients). Both rank for high-intent queries.
- Step 05
Map Pack + GBP weekly cadence
GBP rebuild with Weight Loss Service primary + medical secondaries, service-menu mapping, weekly posts about protocol and program updates, photo strategy. Map Pack is where the "weight loss clinic near me" traffic lives, and it's where telehealth brands can't compete.
- Step 06
Monthly review + regulatory watch
Monthly working session reviewing bookings, rankings, LSA lead quality (where applicable), and ANY regulatory updates (FDA actions, Meta / Google policy changes, state board activity). This is the vertical where the landscape actually moves month-to-month — the program reflects that.
Bookings, show-up, and program enrollment — not raw "leads."
Weight-loss patients are prolific shoppers. A lead form submission in this category often represents a patient filling out forms at 4–6 clinics in the same week. The metrics that actually predict program revenue are further down the funnel.
Booked consultations that show up
Not "leads" — leads are cheap and no-show-prone in weight loss. Booked consultations that show up are the real metric. We feed intake data back into the program to tune content, pricing clarity, and pre-visit communication.
Program enrollment rate (consult → enrolled patient)
The consult-to-enrolled-patient conversion is the biggest revenue lever on a weight-loss account. Driven partly by SEO (content that pre-educates the patient) and partly by the clinic's own intake process. We report it because it tells us whether the SEO content is doing pre-qualification work or just driving tire-kickers.
Map Pack visibility — "weight loss clinic near me" and drug variants
"Weight loss clinic near me" (27,100/mo) + drug-name variants (semaglutide, GLP-1, Wegovy, Mounjaro) — tracked daily, reviewed weekly. This is where the telehealth brands can't show up, so Map Pack dominance is durable.
Branded search growth
Weight-loss patients who enrolled tell three or four friends over the next year. That shows up as branded-search volume growth. It's the cheapest patient acquisition in the program once it starts — and the metric that tells you the program is working as a compounding system, not a paid-leads machine.
Illustrative metrics. Individual clinic results vary by market, intake capacity, and baseline. No guaranteed outcomes — standard FTC endorsement disclaimers apply.
The four hot zones for weight-loss content in 2026.
No healthcare marketing category has seen more regulatory action in the past 24 months than weight loss. The FTC has been active on substantiation. The FDA has been active on compounded-drug advertising. Meta and Google have both updated their weight-loss ad policies. State attorneys general have been active on specific clinic chains. A program built without compliance cleanup is a program exposed on multiple fronts simultaneously.
Four specific surfaces we audit on every weight-loss engagement. None of them requires heavy rework — but all of them need to be checked before content ships.
FTC Section 5 substantiation on weight-loss outcome claims
"Lose 20 lbs in 2 months," "guaranteed results," "no diet required" — these require competent and reliable scientific evidence per FTC Act Section 5. We rewrite or remove unsupported claims. Results language gets representative-results disclaimers where testimonials are used.
Compounded semaglutide equivalence claims
Compounded semaglutide cannot be marketed as equivalent to Wegovy or Ozempic. Clinics that prescribe compounded must distinguish clearly in content and advertising. We audit and rewrite where the distinction is blurred.
Drug-specific promotional content rules
Wegovy, Ozempic, Mounjaro, Zepbound — branded product names trigger additional FDA and manufacturer attention. Content that uses brand names must respect trademark, must not imply off-label use, and must not promise specific outcomes. We use them where appropriate, with the right language.
Telehealth prescribing and state-board scope
If your clinic prescribes GLP-1s via telehealth across states, the website must reflect what's actually legal in each state where you serve. Some states require initial in-person visits; some require specific follow-up cadences. We build state-aware content that doesn't create regulatory exposure.
Common questions.
- Can weight-loss clinics still market semaglutide given the 2024 FDA shortage resolution?
- Yes — with specifics. If your clinic prescribes FDA-approved semaglutide (Wegovy) or tirzepatide (Zepbound / Mounjaro), you can market those with appropriate compliance language. If your clinic still prescribes compounded semaglutide under current rules (which vary by state and by specific prescriber circumstance), that content needs distinct language that does not claim equivalence to the FDA-approved version. We audit each clinic's prescribing posture on the discovery call and build the content to match.
- What's the difference between marketing compounded vs branded (Wegovy, Ozempic, Mounjaro) semaglutide?
- Three practical differences. First, compounded cannot be marketed as equivalent to branded. Second, Google Ads policies apply somewhat differently — branded-drug ads have more restrictive review in some respects but clearer approval paths; compounded sits in more ambiguous territory. Third, patient expectations diverge — branded patients expect insurance billing conversations; compounded patients expect cash-pay clarity. Content has to speak to the right expectation. We separate the content streams in the site architecture so the same page doesn't try to do both.
- Should our weight-loss content address the insurance question directly?
- Yes — directly, early on every program page. Most medical weight-loss programs are cash-pay; trying to hide that or bury it in fine print creates no-shows and lengthens sales cycles. A clear "most of our program is cash-pay; we provide documentation for HSA / FSA / out-of-network reimbursement where eligible" up-front improves conversion. Patients self-select, and the ones who book are pre-qualified. This is one of the most counterintuitively effective moves we make on weight-loss accounts.
- How long until a new weight-loss clinic can rank for "weight loss clinic near me" in a competitive metro?
- In a competitive metro (top-30 MSA), expect 6–12 months of consistent program execution before a new clinic can rank top-3 in the Map Pack for the headline query. In a less competitive metro, 90–150 days is more typical. Drug-specific queries ("semaglutide near me," "wegovy provider near me") often rank faster than the headline because fewer clinics have substantive content on those specific pages. We target both timelines, not just the headline query.
- Do weight-loss patients review differently than hormone or general wellness patients?
- Yes. Weight-loss patients shop multiple clinics simultaneously and review 2–3x as often when prompted, but their reviews are shorter and more outcome-focused ("lost 32 lbs," "program worked for me") — which creates FTC disclaimer obligations that general wellness reviews don't. Our review engine for weight-loss accounts is specifically designed to prompt for substantive, compliant reviews with representative-results disclaimers where needed.
- Should the clinic offer telehealth semaglutide in addition to in-person?
- This is a clinical and business decision, not a marketing decision — we don't recommend either way. What we do: build the content so that whichever model you run, the website reflects it accurately and respects state-by-state telehealth rules. If you offer both, we build dual-model content clearly separating the telehealth experience from the in-person one. Each needs distinct landing pages for the searches that match each intent.
- How do we position against national telehealth weight-loss brands like Hims, Ro, Sequence, or Found?
- Same pattern as TRT. Telehealth brands run great funnels but deliver shallower clinical experiences. The positioning is in-person labs, same-provider continuity, prescription backup when one GLP-1 is out of stock, and faster problem resolution when a side effect shows up. Your SEO content surfaces those advantages directly — and the Map Pack surfaces are a channel telehealth brands structurally can't dominate. Most of our weight-loss wins are in that channel.
Pair this with the rest of the six-surface playbook.
The paired page
Meta Ads for Hormone & Wellness Clinics (hub)
The paid-social side — Facebook and Instagram campaigns that clear Meta's weight-loss ad review and pair with the weight-loss SEO program. Dedicated weight-loss Meta Ads page ships in Sprint 3.
Ready for a post-2024 weight-loss SEO program?
Book a 30-minute discovery call. We'll pull your clinic's current content, flag the claim-language exposure, and show you the three highest-ROI moves in the current regulatory picture.